Hong Zebger-Gong
Senior Medical Director, Global Oncology Clinical Development Daiichi Sankyo
Accomplished Pharmaceutical Physician with over 25 years of experience across academic clinics and the global pharmaceutical industry. Recognized for driving high-impact results as a Clinical Development Lead, steering complex Oncology R&D programs through Phase I-III to successful global regulatory filings and drug approvals
Seminars
Monday 8th March 2027
Evaluating Phase II/III Efficacy & Safety Insights from an ADC in EGFR-Mutated NSCLC
12:00 pm
- Reviewing combined phase II and III efficacy and safety data supporting accelerated approval of the ADC in EGFR-mutated NSCLC
- Exploring key learnings on toxicity management and therapeutic index optimisation drawn from early-phase through late-phase development of the program
- Outlining key safety parameters to take forward in late-stage trials
Monday 8th March 2027
Panel Discussion: Dual Payload & Novel ADCs – Balancing Enhanced Efficacy Against Overlapping Toxicities & Strategies for Effective Translation in Models & in the Clinic
1:30 pm
- How can multiple payloads overcome tumour heterogeneity, resistance, and enhance anti-tumour efficacy?
- Discussing the strategies to mitigate overlapping toxicities, optimise therapeutic windows, and balance increased potency with safety profiles through development
- Examining how preclinical models, biomarker strategies, and translational approaches can better predict clinical outcomes and support the successful development of advanced ADC formats in the clinic